JP2017534571A - 抗体3e10の多価フラグメントおよびその使用方法 - Google Patents

抗体3e10の多価フラグメントおよびその使用方法 Download PDF

Info

Publication number
JP2017534571A
JP2017534571A JP2017511183A JP2017511183A JP2017534571A JP 2017534571 A JP2017534571 A JP 2017534571A JP 2017511183 A JP2017511183 A JP 2017511183A JP 2017511183 A JP2017511183 A JP 2017511183A JP 2017534571 A JP2017534571 A JP 2017534571A
Authority
JP
Japan
Prior art keywords
cells
cell
seq
binding molecule
scfv3e10
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017511183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534571A5 (cg-RX-API-DMAC7.html
Inventor
ジェイムズ イー. ハンセン,
ジェイムズ イー. ハンセン,
リチャード エイチ. ウェイズバート,
リチャード エイチ. ウェイズバート,
フィリップ ダブリュー. ノーブル,
フィリップ ダブリュー. ノーブル,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2017534571A publication Critical patent/JP2017534571A/ja
Publication of JP2017534571A5 publication Critical patent/JP2017534571A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017511183A 2014-08-28 2015-08-27 抗体3e10の多価フラグメントおよびその使用方法 Withdrawn JP2017534571A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043228P 2014-08-28 2014-08-28
US62/043,228 2014-08-28
PCT/US2015/047174 WO2016033321A1 (en) 2014-08-28 2015-08-27 Multivalent fragments of antibody 3e10 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019217791A Division JP2020040987A (ja) 2014-08-28 2019-12-02 抗体3e10の多価フラグメントおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2017534571A true JP2017534571A (ja) 2017-11-24
JP2017534571A5 JP2017534571A5 (cg-RX-API-DMAC7.html) 2018-10-04

Family

ID=54064606

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017511183A Withdrawn JP2017534571A (ja) 2014-08-28 2015-08-27 抗体3e10の多価フラグメントおよびその使用方法
JP2019217791A Withdrawn JP2020040987A (ja) 2014-08-28 2019-12-02 抗体3e10の多価フラグメントおよびその使用方法
JP2022001621A Pending JP2022037244A (ja) 2014-08-28 2022-01-07 抗体3e10の多価フラグメントおよびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019217791A Withdrawn JP2020040987A (ja) 2014-08-28 2019-12-02 抗体3e10の多価フラグメントおよびその使用方法
JP2022001621A Pending JP2022037244A (ja) 2014-08-28 2022-01-07 抗体3e10の多価フラグメントおよびその使用方法

Country Status (4)

Country Link
US (2) US20170291961A1 (cg-RX-API-DMAC7.html)
EP (1) EP3194450A1 (cg-RX-API-DMAC7.html)
JP (3) JP2017534571A (cg-RX-API-DMAC7.html)
WO (1) WO2016033321A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534788A (ja) * 2018-08-31 2021-12-16 イェール ユニバーシティーYale University 三重鎖およびヌクレアーゼベースの遺伝子編集を亢進するための組成物および方法
JP2022500009A (ja) * 2018-08-31 2022-01-04 イェール ユニバーシティーYale University ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
WO2015134607A1 (en) 2014-03-04 2015-09-11 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3471777A1 (en) * 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US11613590B2 (en) * 2017-07-17 2023-03-28 Nucleus Therapeutics Pty. Ltd Binding proteins 1
US20210137960A1 (en) 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
KR20220101073A (ko) 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
WO2021077070A1 (en) 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
WO2022047424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
AU2023228912A1 (en) 2022-03-03 2024-09-19 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
EP4584292A1 (en) 2022-09-09 2025-07-16 Yale University Proteolysis targeting antibodies and methods of use thereof
WO2024140936A1 (en) * 2022-12-30 2024-07-04 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Humanized cell-penetrating antibodies
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507225A (ja) * 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア mab 3E10 ならびにその突然変異体および/または機能性フラグメントを使用する送達システム
JP2014513069A (ja) * 2011-04-01 2014-05-29 イェール ユニバーシティー 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
WO2012145125A1 (en) * 2011-03-25 2012-10-26 4S3 Bioscience Inc. Targeted radionuclides
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507225A (ja) * 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア mab 3E10 ならびにその突然変異体および/または機能性フラグメントを使用する送達システム
JP2014513069A (ja) * 2011-04-01 2014-05-29 イェール ユニバーシティー 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534788A (ja) * 2018-08-31 2021-12-16 イェール ユニバーシティーYale University 三重鎖およびヌクレアーゼベースの遺伝子編集を亢進するための組成物および方法
JP2022500009A (ja) * 2018-08-31 2022-01-04 イェール ユニバーシティーYale University ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法
JP7570107B2 (ja) 2018-08-31 2024-10-21 イェール ユニバーシティー ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法
JP7570106B2 (ja) 2018-08-31 2024-10-21 イェール ユニバーシティー 三重鎖およびヌクレアーゼベースの遺伝子編集を亢進するための組成物および方法

Also Published As

Publication number Publication date
WO2016033321A1 (en) 2016-03-03
US20170291961A1 (en) 2017-10-12
US20200199255A1 (en) 2020-06-25
JP2022037244A (ja) 2022-03-08
JP2020040987A (ja) 2020-03-19
EP3194450A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
JP2022037244A (ja) 抗体3e10の多価フラグメントおよびその使用方法
US10238742B2 (en) Cell penetrating nucleolytic antibody based cancer therapy
US10040867B2 (en) Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
AU2018302110B2 (en) Binding proteins 1
US20260028426A1 (en) Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
CN103874710B (zh) 细胞渗透型抗dna抗体和其抑制dna修复的用途
JP5828901B2 (ja) 新規egfr結合分子およびその免疫抱合体
US10752697B2 (en) Anti-glypican 3 antibody and pharmaceutical composition containing the same
CN103328505A (zh) 非拮抗性egfr结合分子及其免疫偶联物
US20210340279A1 (en) Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
BR112020013244A2 (pt) proteínas de fusão de anticorpo citosina-desaminase de domínio único
JP2019512262A (ja) エンドシアリン結合抗体
KR20240095534A (ko) 화학요법 내성 암의 치료 방법에서 사용하기 위한 항체-약물 접합체
WO2017196764A1 (en) Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
EP4393515A1 (en) Anti-cldn-18.2 antibody-drug conjugate and use thereof
WO2025194038A1 (en) Antibody compositions and methods for targeting extracellular nucleosome proteins
HK40089485B (zh) 抗cldn-18.2抗体药物偶联物及其用途
HK40089485A (en) Anti-cldn-18.2 antibody-drug conjugate and use thereof
WO2026082207A1 (zh) 抗EGFR和cMET双特异性抗体的抗体药物偶联物
WO2024259300A2 (en) Compositions and methods for targeting extracellular dna
HK40111192A (en) Ph-dependent anti-sulfated glycosaminoglycan antibody and antibody-drug conjugate
TW201711702A (zh) 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201027

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210217